Cencora, Inc. (COR)
NYSE:COR
Want to see COR full AI Analyst Report?
COR Stock Chart & Stats
$327.56
$2.86(1.22%)
At close: 4:00 PM EST
$327.56
$2.86(1.22%)
Day’s Range― - ―
52-Week Range$244.82 - $377.54
Previous CloseN/A
Volume440.68K
Average Volume (3M)2.05M
Market Cap
$54.76B
Enterprise Value$64.06B
Total Cash (Recent Filing)$2.24B
Total Debt (Recent Filing)$12.39B
Price to Earnings (P/E)21.1
Beta0.07
Next Earnings
Aug 05, 2026EPS Estimate
4.35Next Dividend Ex-DateN/A
Dividend Yield0.66%
Share Statistics
EPS (TTM)13.12
Shares Outstanding194,561,070
10 Day Avg. Volume1,285,954
30 Day Avg. Volume2,053,066
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue0.19
Enterprise Value/Gross Profit5.62
Enterprise Value/Ebitda12.82
Forecast
1Y Price Target
$345.44Price Target Upside5.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)17.77
Revenue Forecast (FY)$337.94B
Bulls Say, Bears Say
Bulls Say
Scale And Distribution FranchiseCencora’s large-scale distribution and integrated pharma services provide durable competitive advantages: purchasing leverage, logistics scale, and deep manufacturer and provider relationships. This scale lowers per-unit costs, supports contract wins, and creates high switching frictions for customers over months to years.
Gross Profit And Margin ExpansionSustained gross-profit growth and margin improvement indicate durable mix gains from specialty businesses (including OneOncology) and improved pricing/operations. For a low-margin distribution model, incremental margin expansion materially boosts operating income sustainability and buffers against cyclical revenue declines.
Strong Cash Generation And Capital ReturnsRobust quarterly free cash flow, a $3.0B FCF target and a $1B repurchase plan demonstrate durable cash-generation capacity. Consistent FCF enables debt paydown, selective M&A and shareholder returns, supporting long-term value creation even while managing capital for integration and growth.
Bears Say
Elevated LeverageHigh debt relative to equity constrains strategic flexibility and raises sensitivity to interest-cost increases. Elevated leverage reduces the company’s buffer against revenue or margin shocks, limits ability to fund large acquisitions without refinancing, and prolongs the timeline to reach a conservative capital structure.
Declining Trailing Free Cash FlowA meaningful TTM free-cash-flow decline signals higher working-capital demands or timing pressures in distribution. Persistently lower FCF would slow deleveraging, restrict buybacks and limit reinvestment, reducing resilience against sector headwinds and making capital allocation tougher over the medium term.
Structural Revenue HeadwindsSustained revenue pressure from manufacturer list-price cuts, customer account losses, and faster mail-order conversions can persistently depress top-line volume in a low-margin business. Given limited margin cushions, prolonged top-line weakness would strain operating-leverage dynamics and complicate earnings durability.
Cencora News
COR FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Cencora, Inc. lowest stock price was $244.82 and its highest was $377.54 in the past 12 months.
What is Cencora, Inc.’s market cap?
Cencora, Inc.’s market cap is $54.76B.
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 47 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on May 06, 2026. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.818 by -$0.068.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.66%. See more information on Cencora, Inc. dividends here
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 4.35.
How many shares outstanding does Cencora, Inc. have?
Cencora, Inc. has 194,561,070 shares outstanding.
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of $4.75 in its last earnings report, missing expectations of $4.818. Following the earnings report the stock price went down -17.378%.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in COR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$345.44 (5.46% Upside)
$345.44 (5.46% Upside)
Blogger Sentiment
Bullish
COR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 75.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.78%
12-Months-Change
Fundamentals
Return on Equity
115.93%
Trailing 12-Months
Asset Growth
14.69%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong profitability and cash-generation metrics (EPS growth +7.5%, gross profit +16%, operating income +6%), a raised EPS range, improved operating income guidance, robust international performance, and the resumption of $1B share repurchases against material near-term revenue pressures (reduced consolidated revenue guidance from 7%–9% to 4%–6%) driven by WAC price reductions, account losses and faster mail-order brand conversions. Management highlighted transitory items (weather, COVID vaccine comparisons) and acquisition-related expense impacts but maintained confidence in long-term operating income growth and free cash flow generation.View all COR earnings summariesCOR Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations
COR Stock 12 Month Forecast
Average Price Target
$345.44
▲(5.46% Upside)
Technical Analysis
Ownership Overview
0.35% Insiders
30.75% Mutual Funds
16.37% Other Institutional Investors
23.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---